Reuters
14 Jul 2026, 06:19 UTC · 1h ago
AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Reuters
14 Jul 2026, 06:19 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
AstraZeneca will pay Dizal Pharmaceutical $600 million upfront for the global rights to a lung cancer drug. — Significant capital outlay for a strategic asset indicates growth in oncology pipeline, though the upfront cost is a direct cash outflow.
+0.40Which stocks this story touches
Receiving a $600 million upfront payment for the rights to one of its drugs.
Acquiring global rights to a lung cancer drug expands its oncology pipeline.
Continue reading
6 related stories
Top 1 mover · tap to explore
[mutual] AstraZeneca is paying Dizal Pharmaceutical for global rights to one of its lung cancer drugs.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Proactive Investors
1h ago
